1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Daewon Pharmaceutical Co., Ltd

Daewon Pharmaceutical Co., Ltd

KKRX:003220
7,940.00
KRW
+240.00
(+3.12%)
105.15EPS
63.92P/E
168.25BMarket Cap
Nov 12Next Earn
Daewon Pharmaceutical Co., Ltd
KRX:003220
(Korea Stock Exchange)

Recent

price

7,940.00

P/E

ratio

63.92

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
7,214.33
7,045.66
5,775.94
6,954.92
7,966.43
9,654.68
10,781.73
11,712.87
12,899.79
14,303
13,761.05
16,236.49
22,636.74
25,117.16
28,120.01
28,523.52
28,679.53
Revenue per Share
590.61
478.74
401.93
539.35
688.52
790.24
906.62
473.96
1,068.54
1,228.07
786.87
320.39
1,510
1,140
668
-65
122.81
Basic EPS, GAAP
446.16
334.49
417.19
94.19
69.18
113.17
9.81
-593.71
-114.74
-255.66
408.92
490.82
616.79
1,483.51
-1,106.97
8.57
-931.77
Free Cash Flow per Basic Share
97.73
124.75
26.67
30.72
50.68
108.57
152.43
199.48
209.54
220
224.58
143.94
194.76
349.85
298.93
302.93
- -
Dividend per Share
4,422.77
5,245.8
5,167.1
5,632.34
6,156.35
6,813.54
7,480.09
7,786.1
8,506.54
9,500.9
10,080.1
10,335.27
11,966.66
12,558.89
12,843.7
12,406.7
12,488.86
Book Value per Share
4,165.83
4,674.58
4,719.91
5,256.39
5,842.72
6,414.8
7,048.01
7,140.72
7,629.48
8,551.97
8,964.77
8,429.27
10,055.74
10,602.32
10,287.09
9,491.82
9,434.82
Tangible Book Value per Share
20
20
24
23
23
22
22
23
22
22
22
22
21
21
21
21
21
Basic Weighted Avg Shares
144,696
138,875
138,168
158,879
181,985
216,187
240,722
265,462
286,653
317,828
308,501
354,176
478,885
526,952
598,162
605,435
614,636
Sales/Revenue/Turnover
13.87
9.64
9.77
9.78
9.78
10.68
12.11
9.53
10.73
11.05
7.81
5.48
8.98
6.12
4.72
0.58
-0.01
Operating Margin (%)
4,277
3,445
3,777
4,042
4,326
5,979
7,469
8,699
10,399
11,814
15,674
17,805
19,368
17,561
20,095
23,747
24,592
Depreciation Expense
11,846
9,436
9,615
12,321
15,729
17,695
20,242
10,742
23,744
27,289
17,640
6,989
31,944
23,917
14,210
-1,380
2,632
Net Income, GAAP
41.36
26.12
22.21
21.59
26.16
25.44
28.93
56.32
25.39
24.01
27.25
61.42
20.83
9.16
37.47
186.59
74.63
Effective Tax Rate (%)
8.19
6.79
6.96
7.75
8.64
8.19
8.41
4.05
8.28
8.59
5.72
1.97
6.67
4.54
2.38
-0.23
0.43
Profit Margin (%)
43,602
42,680
51,674
58,546
60,730
58,650
60,231
56,626
49,030
59,808
61,259
78,301
79,137
26,603
56,794
40,266
25,689
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
9,000
30,316
30,030
72,240
53,080
35,472
66,489
84,954
62,045
LT Debt
95,088
103,917
112,925
123,251
134,511
148,661
162,013
168,129
183,198
204,216
212,772
218,404
248,765
264,264
284,578
274,578
275,731
Total Equity
12
8.6
9.31
10.05
9.76
11.65
12.86
6.24
11.38
11.09
6.6
2.42
9.42
7.43
3.96
-0.63
-0.01
Return on Invested Capital (%)
12.75
9.31
8.53
10.33
12.08
12.63
13.36
6.63
12.47
11.96
7.28
2.69
10.22
7.37
5.71
-1.05
1.45
Return on Capital (%)
13.81
9.49
8.9
10.49
12.27
12.55
13.08
6.52
13.51
14.05
8.42
3.23
13.59
9.25
5.25
-0.51
0.98
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
117,080
100,318
127,106
LT Borrowings
82,870
82,315
59,531
LT Finance Leases
2,085
2,576
2,514
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
256,130
218,621
168,252

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
256,603
238,489
233,559
Cash, Cash Equivalents & STI
76,475
56,007
66,185
Accounts Receivable, Net
77,119
68,359
53,777
Inventories
97,832
101,916
105,155
Total Current Liabilities
216,337
201,455
207,869
Payables & Accruals
- -
- -
- -
ST Debt
117,080
100,318
127,106
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.43%
5.39%
-3.51%
Free Cash Flow
-665.31%
-19.85%
-100.77%
Net Income, GAAP
18.93%
24.25%
-109.71%
Sales/Revenue/Turnover
11.24%
14.96%
1.22%
Total Cash Common Dividend
14.33%
11.9%
1.12%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
158,301
137,959
156,831
145,070
598,162
2025
157,832
143,856
143,940
159,807
605,435
2026
158,058
152,832
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
436
-37
318
-49.46
668
2025
253
-139
-812.5
634.38
-65
2026
113.01
188
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
298.93
2025
- -
- -
- -
- -
302.93
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Daewon Pharmaceutical Co., Ltd. is a South Korean pharmaceutical company founded in 1958 and headquartered in Seoul. It primarily manufactures and sells a wide range of medicines and medical supplies, focusing on circulatory system drugs, respiratory medicines, antibiotics, chemotherapy agents, and psychoneurosis treatments. Its core product portfolio includes Oramin-F Soft Cap (a multivitamin), Pelubi Tablet (a nonsteroidal anti-inflammatory drug for pain relief), Freefol-MCT Injection (microemulsion propofol targeting anti-exogenous infectious bacteria), Megex-I Suspension (for nutritional supplementation in cancer patients), Trigel Suspension (for gastritis and duodenal ulcer therapy), and Renamezin Cap (a spherical carbonaceous adsorbent for chronic kidney disease). The company operates domestically in South Korea and exports products to approximately 40 countries across Asia, Central and South America, the Middle East, the CIS, and Africa. Recent major developments include a strategic co-development partnership with Ildong Pharmaceutical and its subsidiary Yunovia for next-generation gastroesophageal reflux disease treatments and a potassium-competitive acid blocker drug candidate. In 2025, Daewon Pharmaceutical completed a Phase 1 clinical trial in Vietnam for DW1021, a synthetic pain reliever combining its flagship product Pelubi with Tramadol, marking the company as the first Korean pharmaceutical to conduct such a trial in Vietnam. It plans further clinical trials and product registration there. The company is also advancing its health functional food branding to consolidate market share domestically. Additionally, Daewon reported ongoing research and development efforts in novel H+/K+-ATPase inhibitors for reflux esophagitis treatment. Daewon operates in the specialty and generic drug manufacturing sector, serving healthcare providers and patients primarily in South Korea and various international markets. It maintains advanced production facilities and emphasizes research and development to innovate and expand its product lineup. The company employs over 1,200 employees and continues to solidify its market position through product development, strategic alliances, and geographic expansion with a subsidiary in Vietnam among other initiatives. Overall, Daewon Pharmaceutical remains a significant player in South Korea's pharmaceutical industry with a comprehensive product range, active R&D pipeline, and strategic collaborations for novel drug development and market expansion.